People with impaired immunity invited for repeat vaccination From 19 April on, people who have moderately or severely impaired immunity will receive their invitation for a repeat vaccination against COVID-19.
Most reports received by MEBI in 2021 concerned copper IUDs More reports of suspected adverse effects from copper intrauterine devices (IUDs) were made in 2021 than in previous years, according to the annual report of the Dutch reporting and expertise centre for adverse effects of medical implants (MEBI).
RIVM recalls fill needles for COVID-19 vaccination at supplier’s request As of today, RIVM is recalling the fill needles made by MLS/Sol-Millenium Europe as a precaution, following a safety alert from the supplier. This applies to the SOL-M™ Blunt Fill Needle (REF 110022, LOT 05103013).
Collaboration necessary to ensure the safe reuse of consumer products In a circular economy, products, materials and raw materials are continually reused. For example, consumer products like clothes, packaging and toys.
Update on RIVM report “Silicone breast implants in the Netherlands”, State of Affairs October 2017 In June 2016, RIVM published the results of a study on breast implants in the Netherlands.
RIVM to contribute to new Horizon2020 project on oceans and human health across Europe A new EU Horizon2020 project Seas, Oceans and Public Health in Europe (SOPHIE) will explore the complex interplay between the health of the marine environment and that of humans.
Dutch collaboration in One Health European Joint Programme (EJP) RIVM, Wageningen Bioveterinary Research (WBVR) and the Netherlands Centre for One Health (NCOH) are involved in a recently granted One Health European Joint Programme which will start in January 20
Survey health complaints of women with a silicone breast implant This report provides a broad overview of the health complaints experienced by women with silicone breast implants in the Netherlands.
Efficiency and transparency of clinical drug trials must improve The efficiency and transparency of clinical drug trials in the Netherlands must improve. That concludes Sander van den Bogert in his PhD thesis ‘Trials & Tribulations.